2014
Optimizing linkage and retention to hypertension care in rural Kenya (LARK hypertension study): study protocol for a randomized controlled trial
Vedanthan R, Kamano JH, Naanyu V, Delong AK, Were MC, Finkelstein EA, Menya D, Akwanalo CO, Bloomfield GS, Binanay CA, Velazquez EJ, Hogan JW, Horowitz CR, Inui TS, Kimaiyo S, Fuster V. Optimizing linkage and retention to hypertension care in rural Kenya (LARK hypertension study): study protocol for a randomized controlled trial. Trials 2014, 15: 143. PMID: 24767476, PMCID: PMC4113229, DOI: 10.1186/1745-6215-15-143.Peer-Reviewed Original ResearchMeSH KeywordsBlack PeopleBlood PressureCell PhoneClinical ProtocolsCommunicationCommunity Health ServicesCommunity Health WorkersCost-Benefit AnalysisHealth BehaviorHealth Care CostsHealth Knowledge, Attitudes, PracticeHumansHypertensionKenyaMotivational InterviewingPatient CompliancePatientsProfessional-Patient RelationsResearch DesignRural Health ServicesTime FactorsTreatment OutcomeConceptsCommunity health workersHypertension careBlood pressureHealth workersHypertensive individualsMethods/designThis studyCo-primary outcome measuresNon-communicable disease managementHypertension care programDisability-adjusted life yearsSystolic blood pressureOne-year changeHealth Belief ModelCost-effectiveness analysisUsual careMiddle-income countriesHypertension managementHypertension treatmentControl rateRisk factorsOutcome measuresDesignThis studyBehavioral communication strategyCare programLife yearsPROspective Multicenter Imaging Study for Evaluation of chest pain: Rationale and design of the PROMISE trial
Douglas PS, Hoffmann U, Lee KL, Mark DB, Al-Khalidi HR, Anstrom K, Dolor RJ, Kosinski A, Krucoff MW, Mudrick DW, Patel MR, Picard MH, Udelson JE, Velazquez EJ, Cooper L, investigators P. PROspective Multicenter Imaging Study for Evaluation of chest pain: Rationale and design of the PROMISE trial. American Heart Journal 2014, 167: 796-803.e1. PMID: 24890527, PMCID: PMC4044617, DOI: 10.1016/j.ahj.2014.03.003.Peer-Reviewed Original ResearchConceptsCoronary artery diseasePROMISE trialAnatomical testingProspective Multicenter Imaging StudyDiagnostic strategiesInitial diagnostic strategyMajor procedural complicationsSubsequent care decisionsComposite of deathPrimary end pointLarge pragmatic trialClinical care teamQuality of lifeDiagnostic testing strategiesMultidetector coronaryChest painSymptomatic patientsUnstable anginaArtery diseaseProcedural complicationsRandomized trialsSymptomatic subjectsClinical effectivenessMyocardial infarctionPragmatic trial
2009
Quality of life and economic outcomes with surgical ventricular reconstruction in ischemic heart failure: Results from the Surgical Treatment for Ischemic Heart Failure trial
Mark DB, Knight JD, Velazquez EJ, Howlett JG, Spertus JA, Djokovic LT, Harding TM, Rankin GR, Drew LA, Szygula-Jurkiewicz B, Adlbrecht C, Anstrom KJ, Investigators F. Quality of life and economic outcomes with surgical ventricular reconstruction in ischemic heart failure: Results from the Surgical Treatment for Ischemic Heart Failure trial. American Heart Journal 2009, 157: 837-844.e3. PMID: 19376309, PMCID: PMC2694042, DOI: 10.1016/j.ahj.2009.03.008.Peer-Reviewed Original ResearchMeSH KeywordsAgedCoronary Artery BypassFemaleFollow-Up StudiesHealth Care CostsHeart FailureHeart VentriclesHumansMaleMiddle AgedMyocardial IschemiaPlastic Surgery ProceduresQuality of LifeRetrospective StudiesStroke VolumeSurveys and QuestionnairesTreatment OutcomeUnited StatesVentricular Function, LeftConceptsCoronary artery bypass graft surgerySurgical ventricular reconstructionIschemic heart failureQuality of lifeHeart failureVentricular reconstructionQOL measuresIschemic Heart Failure (STICH) trialKansas City Cardiomyopathy QuestionnaireTotal index hospitalization costsArtery bypass graft surgeryLeft ventricular ejection fractionBetter QOLIndex hospitalization costsBypass graft surgeryHeart failure symptomsHeart Failure TrialVentricular ejection fractionLeft ventricular functionHealth care costsTreatment-related differencesGraft surgeryEjection fractionSurgical treatmentVentricular function
2005
Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT)
Reed SD, Radeva JI, Weinfurt KP, McMurray JJ, Pfeffer MA, Velazquez EJ, Allsbrook JS, Masselink LE, Sellers MA, Califf RM, Schulman KA, Investigators F. Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT). American Heart Journal 2005, 150: 323-329. PMID: 16086938, DOI: 10.1016/j.ahj.2004.08.037.Peer-Reviewed Original ResearchMeSH KeywordsAmbulatory CareAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsCaptoprilDrug CostsGlobal HealthHealth Care CostsHealth ResourcesHeart FailureHospital CostsHospitalizationHumansMyocardial InfarctionProspective StudiesQuality of LifeTetrazolesValineValsartanVentricular Dysfunction, LeftConceptsQuality of lifeMyocardial infarctionAcute Myocardial Infarction trialLower medication costsMyocardial Infarction trialHealth-related qualityLinear mixed-effects regression analysisMultinational clinical trialsMixed-effects regression analysisCaptopril groupStudy medicationCardiovascular morbidityVentricular dysfunctionMost patientsHeart failureACE inhibitorsMedication costsProspective economic evaluationClinical trialsHigh riskPatientsValsartanResource useCaptoprilSignificant differences
2004
Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT)
Reed SD, Friedman JY, Velazquez EJ, Gnanasakthy A, Califf RM, Schulman KA. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). American Heart Journal 2004, 148: 122-128. PMID: 15215801, DOI: 10.1016/j.ahj.2003.12.040.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAgedAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsCost-Benefit AnalysisDrug Therapy, CombinationFemaleFollow-Up StudiesHealth Care CostsHealth ResourcesHeart FailureHospitalizationHumansMaleMiddle AgedOutcome Assessment, Health CareProportional Hazards ModelsRandomized Controlled Trials as TopicTetrazolesValineValsartanConceptsValsartan Heart Failure TrialHeart failure hospitalizationHeart Failure TrialHeart failureACE inhibitorsFailure hospitalizationFailure TrialNew York Heart Association class IIIncremental costChronic heart failureMean incremental costOutpatient physician servicesBackground therapyCardiovascular medicationsNet incremental costClinical benefitPrescribed therapyClinical signsAmbulance transportationPatientsUnit cost estimatesHealth outcomesPlaceboValsartanClass II